Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Aldosterone Synthase Inhibitors
Author(s): Shubh K Patel , Hwee Teoh , Ahreni Saunthar , et al Added: 6 months ago

Cardiovascular Renal Metabolic
The Aldosterone Story: New Chapters
Author(s): Vijay Chopra Added: 7 months ago

Heart Failure
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 1 year ago

Heart Failure

MI/ACS
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 7 months ago

Heart Failure
Emerging Strategies in Aldosterone Inhibition: A Special Focus
Author(s): Vijay Chopra Added: 9 months ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps… View more

Heart Failure
Thomas Kahan
Dr Thomas Kahan is Senior consultant in cardiolgy at the Department of cardiology, Danderyd University Hospital Dr Kahan is on the Editorial Board of European Cardiology Review. Research Interests Neurohormonal control of blood pressure and cardiac function in man. Specifically, we study how the sympatho-adrenal mechanisms and the renin-angiotensin-aldosterone system influence… View more
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Added: 6 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
Nothing to REFINE Yet
Author(s): Gheorghe-Andrei Dan Added: 3 months ago

Guidelines & Statements

Heart Failure
New Insights on HFpEF Treatment
Author(s): Giulio Balestrieri , Raul Limonta , Enrico Ponti , et al Added: 1 year ago

Guidelines & Statements

Heart Failure